ReviewFrontiers in molecular neuroscience2026
Mitochondrial control of blood-brain barrier homeostasis in neuroinflammatory psychiatric disorders.
Review in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammatory mechanisms are increasingly recognized in biologically defined subgroups of psychiatric disorders, yet the cellular interfaces linking peripheral immune activation to brain dysfunction remain incompletely understood. This review examines the blood-brain barrier (BBB) and neurovascular unit (NVU) as dynamic immunometabolic structures whose stability depends on mitochondrial bioenergetics, redox signaling, calcium handling, mitophagy, and innate immune regulation. We integrate human postmortem, neuroimaging, cerebrospinal fluid and circulating biomarker findings with mechanistic evidence from cellular and animal models to examine whether mitochondrial dysfunction may be associated with BBB vulnerability, endothelial activation, altered tight-junction organization, and neuroinflammatory signaling. We discuss how this mitochondrial-BBB axis may contribute to transdiagnostic phenotypes such as cognitive impairment, anhedonia, fatigue, negative symptoms, affective dysregulation, and treatment resistance. Candidate biomarkers, including inflammatory mediators, BBB permeability markers, mitochondrial DNA, bioenergetic readouts, mitophagy markers, and neuroimaging measures, are considered as tools for patient stratification rather than diagnosis. Finally, we evaluate therapeutic implications, including mitochondrial-targeted interventions, BBB-protective strategies, anti-inflammatory approaches, metabolic modulation, and precision psychiatry frameworks. We argue that the mitochondrial regulation of BBB homeostasis represents a promising but still emerging framework for understanding neuroinflammatory psychiatric phenotypes and designing biomarker-guided studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.